Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy

被引：0
|
作者：
Grune, Jana
Benz, Verena
Brix, Sarah
Ban, Zsofia
Salatzki, Janek
Hoeft, Beata
Foryst-Ludwig, Anna
Klopfleisch, Robert
Kolkhof, Peter
Kintscher, Ulrich
机构：
来源：
HYPERTENSION | 2014年 / 64卷
关键词：
hypertrophy; cardioprotective drugs;
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
007
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of Finerenone - a novel non-steroidal mineralocorticoid receptor antagonist in a model of pressure overload-induced cardiac hypertrophy
    Grune, J.
    Benz, V
    Brix, S.
    Ban, Z.
    Janek, S.
    Foryst-Ludwig, A.
    Klopfleisch, R.
    Kolkhof, P.
    Kintscher, U.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S35 - S35
  • [2] The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
    Lavall, D.
    Jacobs, N.
    Mahfoud, F.
    Kolkhof, P.
    Boehm, M.
    Laufs, U.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3326 - 3326
  • [3] The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
    Lavall, Daniel
    Jacobs, Nadine
    Mahfoud, Felix
    Kolkhof, Peter
    Boehm, Michael
    Laufs, Ulrich
    BIOCHEMICAL PHARMACOLOGY, 2019, 168 : 173 - 183
  • [4] Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
    Grune, Jana
    Benz, Verena
    Brix, Sarah
    Salatzki, Janek
    Blumrich, Annelie
    Hoeft, Beata
    Klopfleisch, Robert
    Foryst-Ludwig, Anna
    Kolkhof, Peter
    Kintscher, Ulrich
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2016, 67 (05) : 402 - 411
  • [5] The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management
    Beavers, Craig J.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (12) : 1785 - 1790
  • [6] Effects of Non-Steroidal Mineralocorticoid Antagonist (Finerenone) in Western Diet-Induced Kidney Disease
    Myakala, Komuraiah
    Ribeiro, Patricia de Carvalho
    Wang, Xiaoxin
    Korolowicz, Kyle E.
    Rodriguez, Olga C.
    Albanese, Chris
    Levi, Moshe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 668 - 668
  • [7] The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management
    Craig J. Beavers
    Current Cardiology Reports, 2022, 24 : 1785 - 1790
  • [8] Non-steroidal mineralocorticoid receptor antagonist, finerenone, attenuates obesity- and hypertension-induced cardiomyocyte hypertrophy in a blood pressure-independent manner
    Morikawa, K.
    Arima, Y.
    Fujiyama, A.
    Yamada, T.
    Hanatani, S.
    Yamamoto, E.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [9] The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
    Ulrich Kintscher
    Frank Edelmann
    Cardiovascular Diabetology, 22
  • [10] The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
    Kintscher, Ulrich
    Edelmann, Frank
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
12345